Market revenue in 2023 | USD 1,240.7 million |
Market revenue in 2030 | USD 1,841.9 million |
Growth rate | 5.8% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.88% in 2023. Horizon Databook has segmented the Asia Pacific attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
The market in Asia Pacific is expected to grow at the fastest rate during the forecast period owing to the rising prevalence of mental disorders, including ADHD, and increasing government initiatives to provide better & effective treatment for ADHD. According to the Institute of Mental Health (IMH), there are no local studies available on the prevalence of ADHD.
However, international studies estimate that approximately 5% of the country's pediatric population has ADHD. In addition, the IMH reported 67 new cases of adult ADHD from 2018 to 2020. However, a lack of awareness about ADHD and available pharmacological treatment options may restrain market growth.
Furthermore, the presence of key players and their strategic initiatives are expected to drive market growth. For instance, in February 2022, Siemens Healthineers and HMI Group entered into a partnership to support neuroscience patients by developing a center for excellence to improve diagnosis, treatment, and care in these areas. This partnership was expected to boost the adoption of connected health and provide faster access to care.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific attention deficit hyperactivity disorder market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account